Sana Biotechnology (SANA) AI Stock Analysis

• Market Cap: $451.11M
• Dividend Yield: N/A
• Average Volume (3M): 3.00M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: N/A
• EPS Growth: 19.94%
• Country: US
• Employees: 194
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 225,555,370
• 10 Day Avg. Volume: 3,786,175
• 30 Day Avg. Volume: 2,997,829
• PEG Ratio: -0.09
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.25
• Price Target Upside: 262.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 33 Underperform
• Price Target: ―

Sana Biotechnology's overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.

Positive Factors

Clinical Data

Sana reported positive IST data indicating HIP modified cadaver islet cells sustained immune evasion/C-peptide production in a T1D patient without immunosuppression.

Financial Health

Sana Biotechnology has $152.5M in cash with an expected financial runway into 2026.

Technology Validation

Sana's HIP cells demonstrated the ability to overcome autoimmune and allogeneic immune recognition while remaining functional, indicating promising results for their technology.

Negative Factors

Clinical Data Concerns

Some investors note that the C-peptide levels were significantly lower than normal levels and therefore not enough for the patients to achieve insulin independence.

C-peptide Levels

Some investors note that the C-peptide levels were significantly lower than normal levels and therefore not enough for the patients to achieve insulin independence.

Sana Biotechnology Business Overview & Revenue Model

Company Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

How the Company Makes Money

Sana Biotechnology makes money primarily through the development and commercialization of its proprietary cell engineering platforms and technologies. The company generates revenue through partnerships and collaborations with other biotech and pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies. Additionally, Sana may earn revenue from government grants and research funding, as well as potential future sales of approved therapeutic products. Strategic collaborations and licensing agreements are significant contributors to Sana's earnings, enabling the company to leverage its innovative technologies for broader applications and market reach.

Sana Biotechnology Financial Statement Overview

Summary

Sana Biotechnology faces substantial financial challenges, primarily due to its lack of revenue and consistent losses. While there are signs of improvement in balance sheet equity and operating cash flow management, the company needs to focus on generating revenue and achieving profitability to ensure long-term viability. The reliance on external financing is a potential risk if not supported by future revenue growth.

Income Statement

Sana Biotechnology has not generated any revenue over the past years, leading to consistent negative gross and net profit margins. The company reports significant losses in EBIT and EBITDA, reflecting challenges in achieving profitability. The lack of revenue growth indicates a need for strategic adjustments to capture market opportunities.

Balance Sheet

The company's balance sheet shows moderate stability with a debt-to-equity ratio of 0.38 in 2024. However, the equity ratio of approximately 50% suggests a balanced but slightly leveraged position. The negative equity in previous years has improved, indicating some progress, but the overall financial health remains fragile.

Cash Flow

Sana Biotechnology's cash flow reflects significant negative free cash flow, though there is a slight improvement in operating cash flow relative to net income. The company heavily relies on financing activities, which poses sustainability concerns if revenue generation does not improve.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-30.86M	-27.73M	-17.91M	-10.17M
	EBIT
-272.72M	-326.90M	-272.56M	-356.91M	-286.15M
	EBITDA
-272.72M	-252.39M	-256.94M	-356.91M	-287.03M
	Net Income Common Stockholders
-266.76M	-283.25M	-266.39M	-344.18M	-278.64M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
152.50M	205.19M	434.01M	746.88M	412.00M
	Total Assets
501.02M	565.30M	822.72M	1.13B	730.30M
	Total Debt
94.20M	104.10M	108.25M	110.94M	71.91M
	Net Debt
-33.37M	-29.42M	-68.51M	-142.09M	-340.09M
	Total Liabilities
250.52M	277.79M	323.40M	400.90M	1.15B
	Stockholders Equity
250.50M	287.51M	499.31M	728.50M	-421.18M
Cash Flow		Free Cash Flow
-256.58M	-273.61M	-310.93M	-280.92M	-161.85M
	Operating Cash Flow
-223.15M	-253.58M	-290.05M	-251.05M	-137.98M
	Investing Cash Flow
17.45M	172.01M	210.56M	-245.80M	-252.56M
	Financing Cash Flow
199.75M	31.65M	4.91M	631.75M	435.69M

Sana Biotechnology Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SANA, the sentiment is Neutral. The current price of 2 is above the 20-day moving average (MA) of 1.88, above the 50-day MA of 1.82, and below the 200-day MA of 3.03, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 81.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SANA.

Sana Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	63 Neutral	$773.55M	―	222.83%	―	29.88%	35.11%
Sector *	53 Neutral	$5.19B	3.33	-45.04%	2.83%	17.58%	-0.66%
DNTH	48 Neutral	$576.63M	―	-28.73%	―	189.31%	51.03%
AUTL	45 Neutral	$417.84M	―	-49.97%	―	-14.16%	25.80%
TECX	42 Neutral	$402.30M	―	-30.10%	―	―	-343.40%
SANA	33 Underperform	$451.11M	―	-71.44%	―	―	19.94%
HYREQ		$32.00	―		―	―	―

Sana Biotechnology Corporate Events

Sana Biotechnology Shows Promise with Hypoimmune Platform

Sana Biotechnology announced promising results from its hypoimmune platform (HIP) that show potential in overcoming allogeneic and autoimmune rejection, notably in type 1 diabetes. The company’s approach, which addresses a significant limitation in transplant medicine, could transform treatment options for various diseases, enhancing its industry positioning and offering new hope for patients with unmet medical needs.